Managing PCOS-Related Infertility: Ovulation Induction, In Vitro Fertilization, and In Vitro Maturation



Polycystic ovarian syndrome (PCOS) is a complex endocrine disorder that affects up to 15 % of reproductive-age women. One of the hallmarks of the disorder is anovulation, making infertility an area of high concern within this population. Fortunately, there are several treatment options available to assist women with PCOS to achieve a healthy pregnancy. After exclusion of additional contributing factors to the infertility diagnosis, ovulation induction remains the mainstay in the management of PCOS-related infertility. For anovulatory women with excess body mass, weight loss is the most physiologic method to restore ovulatory cycles. When medical intervention is indicated, clomiphene citrate is considered the gold standard modality for ovulation induction, although aromatase inhibitors are increasingly being utilized in recent years. Alternative approaches include ovarian stimulation with the use of gonadotropins, in vitro fertilization (IVF), and, on an individualized basis, in vitro maturation (IVM). In patients with PCOS, the goal of all fertility treatment modalities is to achieve a singleton live birth, while protecting patient safety, limiting the potential risks of multiple pregnancies, and preventing ovarian hyperstimulation syndrome (OHSS).


Luteinizing Hormone GnRH Agonist Clomiphene Citrate Ovulation Induction GnRH Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM–Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38. e25.PubMedCrossRefGoogle Scholar
  2. 2.
    The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89:505–22.CrossRefGoogle Scholar
  3. 3.
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus criteria and long-term health risks related to polycystic ovary syndrome society. Fertil Steril 2004;81: 19–25.Google Scholar
  4. 4.
    Balen AH, Conway GS, Kaltsas G, Techatraisak K, Manning PJ, West C, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;8:2107–11.Google Scholar
  5. 5.
    Stubbs SA, Hardy K, Da Silva-Buttkus P, Stark LJ, Webber AM, Flanagan AP, et al. Anti-mullerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J Clin Endocrinol Metab. 2005;90:5536–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Pigny P, Merlen Y, Robert C. Cortet-Rudelli, Decanter S, Donard D. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic syndrome. Human Reprod Update. 2008;14:367–78.CrossRefGoogle Scholar
  8. 8.
    Shoham Z, Borenstein R, Lunenfeld B, Pariente C. Hormonal profiles following clomphine citrate therapy in conception and nonconception cycles. Clin Endocrinol. 1990;33:271–8.CrossRefGoogle Scholar
  9. 9.
    Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1470–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Zaazdstra BM, Seidell JC, Van Noord PA, te Velde ER, Habbema JD, Vrieswijk B, et al. Fat and female fecundity: prospective study of effect of body fat distribution on conception rates. BMJ. 1993;306:484–7.CrossRefGoogle Scholar
  11. 11.
    Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive disorders in women. Hum Reprod Update. 2003;9:359–72.PubMedCrossRefGoogle Scholar
  12. 12.
    Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2003;88:812–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovarian syndrome. Clin Endocrinol. 1992;36:105–11.CrossRefGoogle Scholar
  14. 14.
    Palomba S, Falbo A, Giallauria F, Russo T, Rocca M, Tolino A, et al. Six weeks of structured exercise training and hypocaoric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. Hum Reprod. 2010;25(11):2783–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Douchi T, Oki T, Yamesaki H, Nakae M, Imabayashi A, Nagata Y. Body fat patterning in polycystic ovary syndrome women as a predictor of the response to clomiphene. Acta Obstet Gyecol Scand. 2004;83:838–41.Google Scholar
  16. 16.
    Fedorcsak P, Dale PO, Storeng R, Ertzeid G, Bjercki S, Oldereid N, et al. Impact of overweight and underweight on assisted reproduction treatment. Hum Reprod. 2004;19:2523–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Speroff L, Fritz MA. Induction of Ovulation. In: Speroff L, Fritz MA, editors. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011. p. 145–85.Google Scholar
  18. 18.
    Casper RF, Mitwally MFM. A historical perspective of aromatase inhibitors for ovulation induction. Fertil Steril. 2012;98(6):1352–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril. 1986;46:392–6.PubMedGoogle Scholar
  20. 20.
    Young SL, Opsahl MS, Fritz MA. Serum concentrations of enclomiphene and zuclomiphene across consecutive cycles of clomiphene citrate therapy in anovulatory infertile women. Fertil Steril. 1999;71:639–44.PubMedCrossRefGoogle Scholar
  21. 21.
    Ghobadi C, Mirhosseini N, Shiran MR, Moghadamnia A, Lennard MS, Ledger WL, et al. Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. J Clin Pharmacol. 2009;49:147–54.PubMedCrossRefGoogle Scholar
  22. 22.
    ESHRE Capri Workshop Group. Mono-ovulatory cycles: a key goal in profertility programmes. Hum Reprod Update. 2003;9:263–74.CrossRefGoogle Scholar
  23. 23.
    Wu CH, Winkel CA. The effect of therapy initiation day on clomiphene citrate therapy. Fertil Steril. 1989;52:564–8.PubMedGoogle Scholar
  24. 24.
    Practice ACOG. Bulletin. Management of infertility caused by ovulatory dysfunction. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2002;99(2):347–58.CrossRefGoogle Scholar
  25. 25.
    FDA Resource Page. U.S. Food and Drug Administration. Clomiphene Citrate. Accessed 28 Apr 2013.
  26. 26.
    Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril. 2002;77:91–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Costello MF, Misso ML, Wong J, Hart R, Rombauts L, Melder A, et al. The treatment of infertility in polycystic ovary syndrome: a brief update. Aust N Z J Obstet Gynaecol. 2012;52:400–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Fluker MR, Wang IY, Rowe TC. An extended 10-day course of clomiphene citrate (CC) in women with CC-resistant ovulatory disorders. Fertil Steril. 1996;66:761–4.PubMedGoogle Scholar
  29. 29.
    O’Herlihy C, Pepperell RJ, Brown JB, Smith MA, Sandri L, McBain JC. Incremental clomiphene therapy: a new method for treating persistent anovulation. Obstet Gynecol. 1981;58:535–42.PubMedGoogle Scholar
  30. 30.
    Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in polycystic ovary syndrome. N Engl J Med. 2007;356: 551–66.PubMedCrossRefGoogle Scholar
  31. 31.
    Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: Randomized double blind clinical trial. BMJ. 2006;332:1485.PubMedCrossRefGoogle Scholar
  32. 32.
    Tang R, Balen AH. Use of Metformin for women with polycystic ovary syndrome. Hum Reprod Update. 2013;19:1.PubMedCrossRefGoogle Scholar
  33. 33.
    Homburg R. Clomiphene citrate- end of an era? A mini-review. Hum Reprod. 2005;20:2043–51.PubMedCrossRefGoogle Scholar
  34. 34.
    Palomba S, Orio F, Zullo F. Ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2006;86:S26–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update. 1997;3:359–65.PubMedCrossRefGoogle Scholar
  36. 36.
    Messinis IE. Ovulation induction: a mini review. Hum Reprod. 2005;20:2688–97.PubMedCrossRefGoogle Scholar
  37. 37.
    Yilmaz B, Kelekci S, Savan K, Oral H, Mollamahmutoglu L. Addition of human chorionic gonadotropin to clomiphene citrate ovulation induction therapy does not improve pregnancy outcomes and luteal function. Fertil Steril. 2006;85:783–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Update. 1996;2:483–506.PubMedCrossRefGoogle Scholar
  39. 39.
    Ahlgren M, Kallen B, Rannevik G. Outcome of pregnancy after clomiphene therapy. Acta Obstet Gynecol Scand 2976;55(4):371–5.Google Scholar
  40. 40.
    Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-estrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009;(4):CD002249.Google Scholar
  41. 41.
    Tung KH, Wilkens LR, Wu AH, McDuffie K, Namura AM, Kolonel LN, et al. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risks: Revisiting the incessant ovulation hypothesis. Am J Epidemiol. 2005;161:321–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Whittemore AS, Harris R, Itnyre J. and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case–control studies. II: invasive epithelial ovarian cancers in white women. Am J Epidemiol. 1992;136:1184–203.PubMedGoogle Scholar
  43. 43.
    Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331:771–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet. 1995;346:995–1000.PubMedCrossRefGoogle Scholar
  45. 45.
    Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1998;147:1038–42.PubMedCrossRefGoogle Scholar
  46. 46.
    Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril. 1999;71:853–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Mosgaard BJ, Lindegard O, Kjaer SK, Schou G, Anderson AN. Infertility, fertility drugs, and invasive ovarian cancer: a case–control study. Fertil Steril. 1997;67:1005–12.PubMedCrossRefGoogle Scholar
  48. 48.
    Rossing MA, Tang MR, Flagg EW, Weiss LK, Wicklung KG. A case–control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol. 2004;160:1070–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Brinton L. Long-term effects of ovulation stimulating drugs on cancer risk. Reprod Biomed Online. 2007;15:38–44.PubMedCrossRefGoogle Scholar
  50. 50.
    Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of breast cancer in a cohort of infertile women. Gynecol Oncol. 1996;60(1):3–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Zreik T, Mazloom A, Chen Y, Vannucci M, Pinnix C, Fulton S, et al. Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat. 2010;124:13–26.PubMedCrossRefGoogle Scholar
  52. 52.
    Pavone ME, Bulun SE. The use of Aromatase Inhibitors for ovulation induction and superovulation. J Clin Endocrinol Metab. 2013;98(5):1838–44.PubMedCrossRefGoogle Scholar
  53. 53.
    Casper RF, Mitwally MF. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab. 2006;91(3):760–71.PubMedCrossRefGoogle Scholar
  54. 54.
    Mitwally MF, Casper RF. The use of aromatase inhibitor for induction of ovulation in cases of clomiphene citrate failure. Curr Opin Obstet Gynecol. 2002;14:255–63.PubMedCrossRefGoogle Scholar
  55. 55.
    Sammour A, Bijan MM, Tan SL, Tulandi T, et al. Prospective randomized trial comparing the effects of letrazole (LE) and clomiphene citrate (CC) on follicular development, endometrial thickness and pregnancy rate in patients undergoing super-ovulation prior to intrauterine insemination (IUI). Fertil Steril. 2001;76:S110.CrossRefGoogle Scholar
  56. 56.
    Misso ML, Wong J, Teede HJ, Hart R, Rombauts L, Melder AM, et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2012;18:301–12.PubMedCrossRefGoogle Scholar
  57. 57.
    He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. Reprod Biomed Online. 2011;23:91–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Biljan MM, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril. 2005;85 Suppl 1:S95.CrossRefGoogle Scholar
  59. 59.
    Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene cirate. Fertil Steril. 2006;85:1761–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Forman R, Gill S, Moretti M, Tulandi T, Koren G, Casper R. Fetal safety of letrazole and clomiphene citrate for ovulation induction. J Obstet Gynaecol Can. 2007;29:668–71.PubMedGoogle Scholar
  61. 61.
    Richter KS, Bugge KR, Bromer JG, Lev MJ. Relationship between endometrial thickness and embryo implantation based on 1294 cycles of in vitro fertilization with transfer of two blastocyst-stage embryos. Fertil Steril. 2007;87:53–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Legro RS, Kunselman AR, Brzyski RG, Casson PR, Diamond MP, Schlaff WD, et al. The pregnancy in polycystic ovary syndrome II (PPCOSII) trail: rationale and design of a double-bling randomized trial of clomiphene citrate and letrazole for the treatment of infertility in women with polycystic ovary syndrome. Contemp Clin Trials. 2012;33(3):470–81.PubMedCrossRefGoogle Scholar
  63. 63.
    Lunenfeld B. Historical perspectives in gonadotropin therapy. Hum Reprod Update. 2004;10(6):453–67.PubMedCrossRefGoogle Scholar
  64. 64.
    Technical ACOG. Bulletin. Managing the anovulatory state: medical induction of ovulation. Number 197. Committee on technical bulletins of American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1994;47:305–12.CrossRefGoogle Scholar
  65. 65.
    Homburg R, Howles CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update. 1999;5:493–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2006;86(Suppl):S178–83.Google Scholar
  67. 67.
    Calaf Alsina J, Ruiz Balda JA, Romeu Sarrio A, Caballero Fernandez V, Cano Trigo I, Gomez Parga JL, et al. Ovulation induction with a starting dose of 50IU of recombinant follicle stimulation hormone in WHO group II anovulation women: the IO-50 study, a prospective, observational, multicentre, open trial. BJOG. 2003;110:1072–7.PubMedCrossRefGoogle Scholar
  68. 68.
    White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, et al. Induction of ovulation with low-dose follicle-stimulating hormone therapy for polycystic ovary syndrome. Fertil Steril. 1995;64:693–7.Google Scholar
  69. 69.
    Dickey RP, Taylor SN, Lu PY, Sartor BM, Rye PH, Pyrzak R. Risk factors for high-order multiple pregnancy and multiple birth after controlled ovarian hyperstimulation: results of 4,062 intrauterine insemination cycles. Fertil Steril. 2005;83:671–83.PubMedCrossRefGoogle Scholar
  70. 70.
    Tur R, Barri PN, Coroleu B, Buxaderas R, Martinez F, Balasch J. Risk factors for high-order multiple implantation after ovarian stimulation with gonadotropins: evidence from a large series of 1878 consecutive pregnancies in a single centre. Hum Reprod. 2001;16:2124–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Heijnen EM, Eijkemans MH, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:13–21.PubMedCrossRefGoogle Scholar
  72. 72.
    Al-Inany HG, Aboulghar M, Mansour R, Serour GI. Optimizing GnRH antagonist administration: meta-analysis of fixed vs flexible protocol. Reprod Biomed Online. 2005;10:567–70.PubMedCrossRefGoogle Scholar
  73. 73.
    MacDougall MJ, Tan SL, Jacobs HS. In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod. 1992;7:597–600.PubMedGoogle Scholar
  74. 74.
    Ragni G, Vegett W, Riccaboni A, Engl B, Brigante C, Crosignani PG. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod. 2005;20(9):2421–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrick K, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod. 2000;15:526–31.PubMedCrossRefGoogle Scholar
  76. 76.
    Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochran review. Hum Reprod. 2002;17:874–85.PubMedCrossRefGoogle Scholar
  77. 77.
    Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of a LH-RH agonist (triptorelin). Fertil Steril. 2000;73:314–20.PubMedCrossRefGoogle Scholar
  78. 78.
    Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertil Steril. 2012;97(6): 1316–20.PubMedCrossRefGoogle Scholar
  79. 79.
    Kummer N, Benadiva C, Feinn R, Mann J, Nulsen J, Engmann L. Factors that predict the probability of a successful clinical outcome after reduction of oocyte maturation with a gonadotropin-releasing hormone agonist. Fertil Steril. 2011;96(1):63–8.PubMedCrossRefGoogle Scholar
  80. 80.
    Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. 2003;14(5):236–42.PubMedCrossRefGoogle Scholar
  81. 81.
    Natri CO, Ferriani RA, Rocha IA. Ovairan hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet. 2010;27:121–8.CrossRefGoogle Scholar
  82. 82.
    Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab. 1983;57:792–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, et al. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online. 2012;27:134–41.CrossRefGoogle Scholar
  84. 84.
    Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril. 1991;56:213–20.PubMedGoogle Scholar
  85. 85.
    Kol S, Humaidan P. GnRH agonist triggering: recent developments. Reprod Biomed Online. 2013;26:226–30.PubMedCrossRefGoogle Scholar
  86. 86.
    Cha KY, Koo JJ, Ko JJ, Choi DH, Han SY, Yoon TK. Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil Steril. 1991;55:109–13.PubMedGoogle Scholar
  87. 87.
    Buckett WM, Chian RC, Holzer H, Dean N, Usher R, Tan SL. Obstetric outcomes and congenital abnormalities after in vitro maturation, in vitro fertilization and intracytoplasmic sperm injection. Obstet Gynecol. 2007;110(4):885–91.PubMedCrossRefGoogle Scholar
  88. 88.
    Mikkelsen AL, Smith S, Lindenberg S. Impact of oestradiol and inhibin A concentrations on pregnancy rate in in-vitro oocyte maturation. Hum Reprod. 2000;15:1685–90.PubMedCrossRefGoogle Scholar
  89. 89.
    Mikkelsen AL, Smith S, Lindenberg S. Possible factors affecting development of oocytes in in-vitro maturation. Hum Reprod. 2000;15 Suppl 5:11–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Chian RC, Buckett WM, Tan SL. Prospective randomized study of human chorionic gonadotropin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome. Hum Reprod. 2000;15:165–70.PubMedCrossRefGoogle Scholar
  91. 91.
    Von Otte S, Schopper B, Diedrich K, Al-Hasani S. Lessons learned from introducing an in-vitro maturation programme into clinical practice. Reprod Biomed Online. 2005;10(3):75–82.CrossRefGoogle Scholar
  92. 92.
    Cha KY, Chian RC. Maturation in vitro of immature human oocytes for clinical use. Hum Reprod Update. 1998;4:103–20.PubMedCrossRefGoogle Scholar
  93. 93.
    Gomez E, Tarin JJ, Pellicer A. Oocyte maturation in humans: the role of gonadotropins and growth factors. Fertil Steril. 1993;60:40–6.PubMedGoogle Scholar
  94. 94.
    Toth TL, Baka SG, Veech LL, Jones HW, Muasher S, Lanzendorf SE. Fertilization and in vitro development of cryopreserved human prophase I oocytes. Fertil Steril. 1994;61:891–4.PubMedGoogle Scholar
  95. 95.
    Wynn P, Picton HM, Krapez JA, Rutherford AJ, Balen AH, Gosden RG. Pretreatment with follicle stimulating hormone promotes the numbers of human oocytes reaching metaphase II by in-vitro maturation. Hum Reprod. 1998;13:3132–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Mikkelsen AL, Lindenberg S. Benefit of FSH priming of women with PCOS to the in vitro maturation procedure and the outcome: a randomized prospective study. Reproduction. 2001;122:587–92.PubMedCrossRefGoogle Scholar
  97. 97.
    Lin YH, Huang LW, Mu SC, Seow KW, Chung J, Hsieh BC, et al. Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes. Hum Reprod. 2003;18:1632–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Grameau A, Andreadis N, Fatum M, Craig J, Turner K, McVeigh E, Child T. In vitro maturation of in vitro fertilization for women with polycystic ovaries? A case–control study of 194 treatment cycles. Fertil Steril. 2012;98:355–60.CrossRefGoogle Scholar
  99. 99.
    Child TJ, Phillips SJ, Abdl-Jalil AK, Guleki B, Tan SL. A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol. 2002;100:665–70.PubMedCrossRefGoogle Scholar
  100. 100.
    Le Du A, Kadoch IJ, Bourcigaux N, Doumerc S, Bourrier MC, Chevalier N, et al. In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience. Hum Reprod. 2005;20:420–4.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Obstetrics, Gynecology and Reproductive SciencesYale School of MedicineNew HavenUSA

Personalised recommendations